The Diabetes Educator

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Neumiller, J. J.
Right arrow Articles by Campbell, R. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neumiller, J. J.
Right arrow Articles by Campbell, R. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
The Diabetes Educator, Vol. 34, No. 2, 183-200 (2008)
DOI: 10.1177/0145721708316620
© 2008 American Association of Diabetes Educators; Published by SAGE Publications

PHARMACY UPDATE

Looking to the Future

Focus on DPP-4 Inhibitors for the Treatment of Type 2 Diabetes and Emerging Therapies

Joshua J. Neumiller, PharmD, Peggy Soule Odegard, PharmD, BCPS, CDE, John R. White, Jr., PA-C, PharmD, Stephen M. Setter, PharmD, CDE and R. Keith Campbell, RPh, MBA, CDE, FASHP

From the Department of Pharmacotherapy, Washington State University/Elder Services, Spokane, Washington (JJN, SMS); School of Pharmacy, University of Washington, Seattle (PSO); and Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman (RKC), and Spokane (JRW).

Correspondence to Joshua J. Neumiller, PharmD, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, 5125 North Market Street, Spokane, WA 99217 (jneumiller{at}wsu.edu).

Strong evidence exists demonstrating the benefits of tight glycemic control in type 1 and type 2 diabetes mellitus patients, but glycemic goals are not adequately achieved for many patients. Advancement in the knowledge surrounding the physiology of endogenous glucoregulatory peptide hormones, such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, has led to new therapeutic targets for the treatment of type 2 diabetes mellitus. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide practitioners with a novel mechanism of action to use for combination therapies for the treatment of type 2 diabetes mellitus. This article, part 3 of a 3-part series, reviews the new class of medications known as DPP-4 inhibitors as well as discusses a future buccal insulin formulation, Oral-LynTM, on the horizon for the treatment of diabetes mellitus.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?